Cellectis announces the settlement and delivery of its ADS offering and the exercise of the over-allotment option of the guarantor banks

NEW YORK, 07 Feb. 11, 2023 (GLOBE NEWSWIRE) — Cellectis (“Cellectis” or the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company, which uses its genome-editing platform to deliver cell therapies and genes that save lives, announced today:

CLLS99 – FO 2023 Press Release – Closing and Greenshoe (French)(1535386016.2) (1).pdf